Insider Purchases: Inside the Buy
Tag: featured-insiders
Lumen Technologies: The Turnaround Nobody Believed (But the CEO Keeps Adding)
Lumen was left for dead—then the CEO kept buying, debt vanished, and AI demand showed up. A fun, honest look at LUMN’s comeback, risks, and why the stock may need a breather before the next sprint.
Enphase Energy: The Comeback Nobody Believed (But the CEO Keeps Buying)
Enphase Energy fell hard after its solar boom—but the CEO keeps buying, institutions still dominate the float, and shorts are piled in. Here’s why ENPH might be starting to sync back in—and what investors should really watch. 🌞🔋
CEO Buys Shares of International Paper: Toilet, Shredded, or Stationery?
International Paper is mid-divorce, mid-restructuring — and its CEO just bought $2M of stock. A messy, event-driven value play with real risk and real conviction.
CEO Purchases Abbott Shares, But the Stock Carries Risks
Abbott’s CEO just stepped in with a $2M insider buy — analysts are bullish, shorts are scarce, and institutions remain locked in. Tempting? Yes. Risk-free? Not quite.
CEO and COO Buy Shares of RLI — Exceptionally Run Insurer, but Not Without Storm Clouds
RLI Corp is exceptionally well run, with insider buying and 30 years of underwriting profits — but forward valuation and catastrophe risk argue for patience, not haste.
CEO Buys More of This Warren Buffett Favorite: Ally Financial Is Up 30% Since Our Bullish Call — Buy More?
Ally Financial is up nearly 30% since our bullish call — and the CEO just bought almost $1M more stock. With Buffett still onboard, analysts bullish, and valuation cheap, this value story may not be done.
Ryan Cohen Buys More GameStop; Time to Play — or Make This Story Short?
Ryan Cohen doubles down on GameStop. Shorts stay crowded. Analysts stay bearish. But profits, cash, and conviction are back. Is GME still a meme — or a mispriced turnaround? 🎯🎮
Insider Buys Shares of Mainz Biomed: Promising Science, Precarious Finances
Mainz Biomed’s cancer-screening science is compelling — and an insider just bought big. But with heavy losses, dilution risk, and a going-concern warning, MYNZ is a biotech moonshot best approached with extreme caution.
Update on High-Risk, High-Reward Intellia Therapeutics: Another Insider Buys — Should You?
NTLA is the kind of stock that tests both your thesis and your pulse. Short interest sits around 36%, the FDA put a key trial on hold, and yet directors just bought ~$2.4M in shares. Here’s the fun-but-serious update on the squeeze setup, the catalysts, and the risks.
Key Director Buys United Natural Foods — Are UNFI Shares No Longer “Unfit” for Your Portfolio?
A key director steps in. Institutions already dominate ownership. Valuation looks compressed. United Natural Foods may not be flashy — but the risk/reward is getting interesting.